Article Text

PDF
OC-045 Efficacy & safety of dose adjustment & delayed response to ustekinumab in moderate–severe crohn’s disease patients: results from im-uniti maintenance study
  1. B Sands1,
  2. C Gasink2,
  3. D Jacobstein2,
  4. L Gao2,
  5. J Johanns2,
  6. P Szapary2,
  7. J Colombel1,
  8. S Targan3,
  9. S Ghosh4,
  10. W Sandborn5
  1. 1Icahn School of Medicine at Mt Sinai, New York
  2. 2Janssen RandD LLC, Pennsylvania
  3. 3Cedars-Sinai Medical Centre, Los Angeles, USA
  4. 4University of Calgary, Calgary, Canada
  5. 5University of California San Diego, La Jolla, USA

Abstract

Introduction Ustekinumab (UST) induced/maintained clinical response (CR) and remission (CRM) in mod-severe Crohn’s disease (CD) as shown in 2 induction (UNITI-1 and 2) and 1 maintenance (IM-UNITI) RCT, placebo (PBO) controlled phIII trials. We evaluated UST efficacy in 2 more grps in IM-UNITI: pts undergoing dose adjustment after loss of response (LOR) and pts without a CR to IV UST during induction and had an additional SC dose.

Method Pts achieving CR after single dose IV induction randomised to SC PBO, UST 90 mg/q12w or q8w. Pts meeting LOR criteria (i.e. CDAI ≥220 and a≥100 point ←from baseline maintenance CDAI score, between wks 8–32 of IM-UNITI trial) underwent a single dose adjustment as follows: PBO→q8w, q12w→q8w, and q8w→q8w (no dose adjustment) and assessed for CR (≥100 point ↓in CDAI) and CRM (CDAI <150) 16 wks later. Separately, UST pts not in CR 8 wks after IV dose given SC UST 90 mg and if CR 8 wks later stayed on q8w.

Results 51 (39%), 29 (23%), and 28 (22%) pts in PBO, q12w and q8w grps, respectively, had dose adjustment after meeting LOR criteria. We observed CRM and CR in 39% and 71% of pts adjusting PBO→q8w (situation similar to drug holiday), 41%–55% in q12w→q8w grp and 32%–46% in q8w→q8w grp assessed 16 wks later respectively (Table 1). Median CDAI change after adjustment was −121,–141 and −78.5 in PBO→q8w, q12w→q8w and q8w→q8w grs, respectively. UST 467 pts not in response after IV dose,50.5%–28.9% had CR and CRM 8 wks after 1 extra UST dose (90 mg SC). Of 251 of these pts continued dosing at wk 8 of maintenance, 68.1% had CR and 50.2% CRM at wk 44. No ←or changes in AEs seen among dose adjustment pts.

Conclusion Pts meeting LOR criteria, dose adjustment from UST 90 mg/q12w to q8w had some additional clinical benefit vs pts remaining on UST 90 mg/q8w. Initial induction non-responders pts can benefit from continued treatment with at least 1 SC UST dose 8 wks after IV induction.

Disclosure of Interest B. Sands: None Declared, C. Gasink Conflict with: Janssen R and D, LLC, D. Jacobstein Conflict with: Janssen R and D, LLC, L. Gao Conflict with: Janssen R and D, LLC, J. Johanns Conflict with: Janssen R and D, LLC, P. Szapary Conflict with: Janssen R and D, LLC, J. Colombel: None Declared, S. Targan: None Declared, S. Ghosh: None Declared, W. Sandborn: None Declared

  • Crohn’s disease
  • dose adjustment
  • ustekinumab

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.